Genistein, an inhibitor of tyrosine kinase, prevents the antiarrhythmic effects of preconditioning

Zahra Fatehi-Hassanabad, J. Parratt

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The possible involvement of tyrosine kinase in the signal transduction processes associated with the antiarrhythmic effects of ischaemic preconditioning was assessed by the administration, prior to the preconditioning stimulus, of the tyrosine kinase inhibitor genistein (5 mg/kg i.v.) to pentobarbitone anaesthetised male rats. The hearts were then removed, perfused by the Langendorff technique and preconditioned by a single brief (3 min) coronary artery occlusion prior to the 30 min test ischaemic insult. Preconditioning reduced ventricular arrhythmias during occlusion (e.g., premature ventricular beats from 333 ± 60 in controls to 52 ± 5 in preconditioned hearts; P <0.05) but this protective effect was not observed in the hearts of rats given genistein (272 ± 37 premature beats). A similar abolition of the protective effects of preconditioning could be demonstrated in hearts perfused in vitro with genistein (100 μM). This suggests the involvement of tyrosine kinase activation in this powerful form of endogenous cardioprotection.

Original languageEnglish
Pages (from-to)67-70
Number of pages4
JournalEuropean Journal of Pharmacology
Volume338
Issue number1
DOIs
Publication statusPublished - Oct 29 1997

Fingerprint

Genistein
Protein-Tyrosine Kinases
Premature Cardiac Complexes
Ischemic Preconditioning
Ventricular Premature Complexes
Coronary Occlusion
Pentobarbital
Cardiac Arrhythmias
Signal Transduction
Coronary Vessels

Keywords

  • Arrhythmias
  • Genistein
  • Preconditioning
  • Tyrosine kinase
  • Ventricular

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Genistein, an inhibitor of tyrosine kinase, prevents the antiarrhythmic effects of preconditioning. / Fatehi-Hassanabad, Zahra; Parratt, J.

In: European Journal of Pharmacology, Vol. 338, No. 1, 29.10.1997, p. 67-70.

Research output: Contribution to journalArticle

@article{f325cddbc5824b33b4bdbe035526621e,
title = "Genistein, an inhibitor of tyrosine kinase, prevents the antiarrhythmic effects of preconditioning",
abstract = "The possible involvement of tyrosine kinase in the signal transduction processes associated with the antiarrhythmic effects of ischaemic preconditioning was assessed by the administration, prior to the preconditioning stimulus, of the tyrosine kinase inhibitor genistein (5 mg/kg i.v.) to pentobarbitone anaesthetised male rats. The hearts were then removed, perfused by the Langendorff technique and preconditioned by a single brief (3 min) coronary artery occlusion prior to the 30 min test ischaemic insult. Preconditioning reduced ventricular arrhythmias during occlusion (e.g., premature ventricular beats from 333 ± 60 in controls to 52 ± 5 in preconditioned hearts; P <0.05) but this protective effect was not observed in the hearts of rats given genistein (272 ± 37 premature beats). A similar abolition of the protective effects of preconditioning could be demonstrated in hearts perfused in vitro with genistein (100 μM). This suggests the involvement of tyrosine kinase activation in this powerful form of endogenous cardioprotection.",
keywords = "Arrhythmias, Genistein, Preconditioning, Tyrosine kinase, Ventricular",
author = "Zahra Fatehi-Hassanabad and J. Parratt",
year = "1997",
month = "10",
day = "29",
doi = "10.1016/S0014-2999(97)01299-5",
language = "English",
volume = "338",
pages = "67--70",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Genistein, an inhibitor of tyrosine kinase, prevents the antiarrhythmic effects of preconditioning

AU - Fatehi-Hassanabad, Zahra

AU - Parratt, J.

PY - 1997/10/29

Y1 - 1997/10/29

N2 - The possible involvement of tyrosine kinase in the signal transduction processes associated with the antiarrhythmic effects of ischaemic preconditioning was assessed by the administration, prior to the preconditioning stimulus, of the tyrosine kinase inhibitor genistein (5 mg/kg i.v.) to pentobarbitone anaesthetised male rats. The hearts were then removed, perfused by the Langendorff technique and preconditioned by a single brief (3 min) coronary artery occlusion prior to the 30 min test ischaemic insult. Preconditioning reduced ventricular arrhythmias during occlusion (e.g., premature ventricular beats from 333 ± 60 in controls to 52 ± 5 in preconditioned hearts; P <0.05) but this protective effect was not observed in the hearts of rats given genistein (272 ± 37 premature beats). A similar abolition of the protective effects of preconditioning could be demonstrated in hearts perfused in vitro with genistein (100 μM). This suggests the involvement of tyrosine kinase activation in this powerful form of endogenous cardioprotection.

AB - The possible involvement of tyrosine kinase in the signal transduction processes associated with the antiarrhythmic effects of ischaemic preconditioning was assessed by the administration, prior to the preconditioning stimulus, of the tyrosine kinase inhibitor genistein (5 mg/kg i.v.) to pentobarbitone anaesthetised male rats. The hearts were then removed, perfused by the Langendorff technique and preconditioned by a single brief (3 min) coronary artery occlusion prior to the 30 min test ischaemic insult. Preconditioning reduced ventricular arrhythmias during occlusion (e.g., premature ventricular beats from 333 ± 60 in controls to 52 ± 5 in preconditioned hearts; P <0.05) but this protective effect was not observed in the hearts of rats given genistein (272 ± 37 premature beats). A similar abolition of the protective effects of preconditioning could be demonstrated in hearts perfused in vitro with genistein (100 μM). This suggests the involvement of tyrosine kinase activation in this powerful form of endogenous cardioprotection.

KW - Arrhythmias

KW - Genistein

KW - Preconditioning

KW - Tyrosine kinase

KW - Ventricular

UR - http://www.scopus.com/inward/record.url?scp=0030709476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030709476&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(97)01299-5

DO - 10.1016/S0014-2999(97)01299-5

M3 - Article

C2 - 9408004

AN - SCOPUS:0030709476

VL - 338

SP - 67

EP - 70

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -